• Free for qualified executives and consultants to industry

  • Receive quarterly issues of Area Development Magazine and special market report and directory issues


BioTechnique Opens York County, Pennsylvania, Pharmaceutical Manufacturing Campus

A pharmaceutical contract development manufacturing company, BioTechnique opened its new pharmaceutical manufacturing facility in York County, Pennsylvania. The $22 million project is expected to create 100 jobs in the region.

BioTechnique purchased the formerly vacant 160,000 square-foot Unilife pharmaceutical manufacturing facility and invested in infrastructure, new equipment, and extensively training employees. The relocation included the transfer of equipment, staff, and customers to Conewago Township.

“We are grateful for the support from the York County Economic Alliance, the Governor’s Action Team, and Governor Wolf for their generous support to enable BioTechnique to relocate from Wisconsin to Pennsylvania,” said CEO of PSC Biotech and General Manager of BioTechnique John Clapham “We are excited to become a contributor in the success of the Pennsylvania economy”.

The company received a funding proposal from Pennsylvania Department of Community and Economic Development (DCED) for a $500,000 Pennsylvania First grant as an incentive, a $200,000 workforce development grant to help the company train workers, a $2 million Pennsylvania Industrial Development Authority loan,and was encouraged to apply for the department’s Manufacturing Tax Credit program.

“The YCEA is honored to welcome PSC biotech to York County,” said Kevin Schreiber, YCEA President and CEO. “This is testament to our Commonwealth and County’s rich manufacturing and life science industries. PSC brings more than two decades providing life sciences with essential services to ensure that healthcare products are developed, manufactured and distributed to the highest standards, Biotech will generate an estimated 100 jobs over the next three years.”

The company manufactures sterile injectable drugs that are highly potent. As a pharmaceutical contract development manufacturing operation, it provides development services for next generation cancer therapies, novel vaccines, hormonal therapies, and DEA controlled substances.

Exclusive Research